Cargando…
Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751553/ https://www.ncbi.nlm.nih.gov/pubmed/31686818 http://dx.doi.org/10.2147/IJN.S211898 |
_version_ | 1783452634574749696 |
---|---|
author | Lee, Chen-Hung Hsieh, Ming-Jer Chang, Shang-Hung Hung, Kuo-Chun Wang, Chao-Jan Hsu, Ming-Yi Juang, Jyuhn-Huarng Hsieh, I-Chang Wen, Ming-Shien Liu, Shih-Jung |
author_facet | Lee, Chen-Hung Hsieh, Ming-Jer Chang, Shang-Hung Hung, Kuo-Chun Wang, Chao-Jan Hsu, Ming-Yi Juang, Jyuhn-Huarng Hsieh, I-Chang Wen, Ming-Shien Liu, Shih-Jung |
author_sort | Lee, Chen-Hung |
collection | PubMed |
description | BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated. RESEARCH DESIGN AND METHODS: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography. RESULTS: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group. CONCLUSION: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases. |
format | Online Article Text |
id | pubmed-6751553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67515532019-11-04 Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo Lee, Chen-Hung Hsieh, Ming-Jer Chang, Shang-Hung Hung, Kuo-Chun Wang, Chao-Jan Hsu, Ming-Yi Juang, Jyuhn-Huarng Hsieh, I-Chang Wen, Ming-Shien Liu, Shih-Jung Int J Nanomedicine Original Research BACKGROUND: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated. RESEARCH DESIGN AND METHODS: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography. RESULTS: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group. CONCLUSION: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases. Dove 2019-09-13 /pmc/articles/PMC6751553/ /pubmed/31686818 http://dx.doi.org/10.2147/IJN.S211898 Text en © 2019 Lee et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lee, Chen-Hung Hsieh, Ming-Jer Chang, Shang-Hung Hung, Kuo-Chun Wang, Chao-Jan Hsu, Ming-Yi Juang, Jyuhn-Huarng Hsieh, I-Chang Wen, Ming-Shien Liu, Shih-Jung Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title | Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title_full | Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title_fullStr | Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title_full_unstemmed | Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title_short | Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
title_sort | nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751553/ https://www.ncbi.nlm.nih.gov/pubmed/31686818 http://dx.doi.org/10.2147/IJN.S211898 |
work_keys_str_mv | AT leechenhung nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsiehmingjer nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT changshanghung nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hungkuochun nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT wangchaojan nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsumingyi nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT juangjyuhnhuarng nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsiehichang nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT wenmingshien nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT liushihjung nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo |